MODERNA INC (MRNA) Stock Price, Quote, News and Summary
NASDAQ:MRNA - Nasdaq - US60770K1079 - Common Stock
MRNA Quote and Key Statistics
MODERNA INC
NASDAQ:MRNA (1/17/2025, 8:15:57 PM)
Premarket: 35.15 +1.09 (+3.2%)34.06
+0.3 (+0.89%)
MRNA Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -14.07% | ||
| ROE | -18.65% | ||
| Debt/Equity | 0.05 |
MRNA Performance and Technical Analysis
MRNA Ownership and Analysts
MRNA Latest News and Analysis
Curious about the S&P500 stocks that are in motion on Thursday? Join us as we explore the top movers within the S&P500 index during today's session.
Which S&P500 stocks are moving on Thursday?
Tuesday's session: top gainers and losers in the S&P500 index
Top S&P500 movers in Tuesday's session
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Monday.
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Monday.
These S&P500 stocks are the most active in today's session
Activity analysis of S&P500 on 2025-01-13: most active stocks in today's session.
3M, Netflix And 3 Stocks To Watch Heading Into Tuesday
US stock futures trading higher on Tuesday. Stocks to watch: 3M, D.R. Horton, Moderna, United Airlines, Netflix.
Moderna, GameStop And Snap Are Among Top Large-Cap Losers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
Eleven large-cap stocks were the worst performers in the last week. Short positions announced for FTAI, revenue updates for MRNA, and price forecasts changed for GME, SNAP, RKLB, NTRA, LLY, ICLR, BNTX, NVO, and BMRN.
About MRNA
Company Profile
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Cambridge, Massachusetts and currently employs 5,600 full-time employees. The company went IPO on 2018-12-07. The firm is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). The company is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Its diverse development pipeline consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development. Its products include COVID-19 vaccines (mRNA-1273/Spikevax, next-generation mRNA-1283), RSV vaccine (mRNA-1345), Seasonal influenza vaccines (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030), Combination vaccines (mRNA-1083, mRNA-1230, mRNA-1045 and mRNA-1365), CMV vaccine (mRNA-1647), EBV vaccine (mRNA-1189 and mRNA-1195) and others.
Company Info
MODERNA INC
325 Binney Street
Cambridge MASSACHUSETTS 02139 US
CEO: Stephane Bancel
Employees: 5600
Company Website: https://www.modernatx.com/
Investor Relations: https://investors.modernatx.com/
Phone: 16177146500
MRNA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.96 | 303.17B | ||
| AMGN | AMGEN INC | 14.16 | 146.27B | ||
| GILD | GILEAD SCIENCES INC | 20.73 | 114.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 827.45 | 108.68B | ||
| REGN | REGENERON PHARMACEUTICALS | 15 | 74.90B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.30B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.76B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.97B | ||
| ONC | BEIGENE LTD-ADR | N/A | 22.37B | ||
| NTRA | NATERA INC | N/A | 20.91B | ||
| BIIB | BIOGEN INC | 8.61 | 20.48B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.76 | 16.02B |